Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 27,855 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo and sham treatment Clear all

Conditions: Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
Interventions: EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Placebo, Antipsychotic therapy; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BI 1015550, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Clearwater, Florida • Gainesville, Florida • Kansas City, Kansas + 8 more

Conditions: Healthy
Interventions: BIIB033, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics
Interventions: MLN3126, MLN3126 Matched Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Advanced Cancers
Interventions: Atorvastatin, Fish Oil Supplement, Placebo; Drug · Dietary Supplement · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV-1 Infection
Interventions: Islatravir, Ulonivirine, BIC/FTC/TAF, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: ORJ-001, Placebo; Drug · Other
Lead sponsor: Oorja Bio, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Doral, Florida • DuBois, Pennsylvania

Conditions: IgA Glomerulonephritis
Interventions: omega-3 fatty acids, prednisone, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Up to 40 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Heart Failure
Interventions: RLX030, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 6,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 105
States / cities: Huntsville, Alabama • Montgomery, Alabama • Tucson, Arizona + 76 more

Conditions: Primary Hyperoxaluria
Interventions: Oxabact OC5 - Oxalobacter formigenes HC-1, Placebo; Biological · Other
Lead sponsor: OxThera; Industry
Eligibility: 2 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Heart Failure
Interventions: HNO Donor, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 24
States / cities: Tucson, Arizona • Gainesville, Florida • Tampa, Florida + 16 more

Conditions: CRC (Colorectal Cancer)
Interventions: Ruxolitinib, Regorafenib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 57
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 54 more

Conditions: Stress Disorder
Interventions: Guanfacine Extended Release, Mindfulness Skills Therapy, Placebo; Drug · Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 10 Years to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Aging, Cognitive Change
Interventions: Cocoa Extract, Cocoa Extract Placebo, Multivitamin, Multivitamin placebo; Dietary Supplement
Lead sponsor: Columbia University; Other
Eligibility: 65 Years and older
Enrollment: 3,959 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
Interventions: Lucinactant 175 mg/kg, Lucinactant 90 mg/kg, Placebo; Drug
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 3 Days to 10 Days
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Warrington, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: LOVAZA Omega 3-acid ethyl esters, LOVAZA, placebo; Drug · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hyperoxaluria
Interventions: Tenapanor, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Coronary Artery Disease
Interventions: Methotrexate, Colchicine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acromegaly, Growth Hormone Deficiency, Pituitary Disease
Interventions: Recombinant human growth hormone, Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: AMP-110, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Anniston, Alabama • Orlando, Florida • Palm Harbor, Florida + 4 more

Conditions: Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions: ATX-101, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 65 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Bradenton, Florida + 3 more

Conditions: Colitis, Ulcerative
Interventions: ST-0529; Drug
Lead sponsor: Sublimity Therapeutics Holdco Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Palm Springs, California • Largo, Florida • New Port Richey, Florida + 4 more

Conditions: Photorefractive Keratectomy
Interventions: nepafenac 0.1%, ketorolac 0.4%; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 19 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: 22q11 Deletion Syndrome
Interventions: NB-001, Placebo; Drug · Other
Lead sponsor: Nobias Therapeutics, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania • Seattle, Washington

Search by objective public record fields.

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants

Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

Study of ORJ-001 for the Treatment of IPF

Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure

Study of Ruxolitinib in Colorectal Cancer Patients

Guanfacine Extended Release and Mindfulness Skills Therapy

Investigating the Effects of Cocoa Flavanol on Cognition Assessed Online

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

Effects of Fish Oil on Post Ablation Arrhythmias

A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.

Inflammation and Coronary Endothelial Function

Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency

Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome